Ekert H, Smibert E, Exton J
Department of Clinical Haematology, Royal Children's Hospital, Parkville, Vic.
Med J Aust. 1987 Sep 7;147(5):230-3. doi: 10.5694/j.1326-5377.1987.tb133415.x.
Twelve boys with haemophilia and factor VIII inhibitors have received initial treatment for each episode of bleeding with prothrombin-complex concentrate. The follow-up period for these boys has ranged from two months to 14 years, and a total of 732 bleeding episodes were reviewed. Each boy underwent a full clinical and radiological assessment of knee-joint function, and this was compared with knee-joint function in 29 patients with severe haemophilia but without factor VIII antibodies. A change of treatment from prothrombin-complex concentrate to some other form of therapy was considered to be required in only 4% of the bleeding episodes. Of 10 severe bleeding episodes, five episodes clearly were controlled with prothrombin-complex concentrate, but five episodes necessitated alternative treatment. Four of the 12 families considered prothrombin-complex concentrate as relatively ineffective. All boys who were older than 10 years of age showed grade-1 or grade-2 impairment of knee-joint mobility, as well as radiological evidence of moderate-to-severe knee-joint changes. In the group of haemophiliac patients who were older than 10 years of age and did not have factor VIII antibodies, only 10 of the 58 knee-joints that were examined showed grade-1 or grade-2 functional impairment. Although prothrombin-complex concentrates were effective in the control of the majority of minor bleeding episodes, they were effective in only 50% of severe episodes of bleeding and did not prevent the early development of haemophilic arthropathy.
12名患有血友病且体内有因子VIII抑制物的男孩,每次出血发作时均接受了凝血酶原复合物浓缩剂的初始治疗。这些男孩的随访期为2个月至14年,对总共732次出血发作进行了回顾。对每个男孩的膝关节功能进行了全面的临床和放射学评估,并与29名患有严重血友病但无因子VIII抗体的患者的膝关节功能进行了比较。仅4%的出血发作被认为需要从凝血酶原复合物浓缩剂改为其他某种治疗形式。在10次严重出血发作中,5次明显通过凝血酶原复合物浓缩剂得到了控制,但5次需要替代治疗。12个家庭中有4个认为凝血酶原复合物浓缩剂相对无效。所有年龄超过10岁的男孩均表现出1级或2级膝关节活动障碍,以及中度至重度膝关节改变的放射学证据。在年龄超过10岁且无因子VIII抗体的血友病患者组中,所检查的58个膝关节中只有10个表现出1级或2级功能障碍。尽管凝血酶原复合物浓缩剂在控制大多数轻度出血发作方面有效,但在仅50%的严重出血发作中有效,且不能预防血友病性关节病的早期发展。